Three High ROE Stocks With Quietly Powerful Balance Sheets

Markets are wrestling with higher inflation, rising bond yields and volatile energy prices, so quality balance sheets matter more than ever. When borrowing costs and policy expectations shift frequently, companies with strong return on equity, resilient past performance and solid finances can give you cleaner exposure to long term growth stories, without relying on heavy leverage or speculative turnarounds. This article focuses on a curated screener that looks exactly for that mix of quality and financial strength, and then highlights 3 stocks from the list that stand out for further research.

Overview: Reddit operates a large social discussion platform where users gather in interest based communities to share content, ask questions, trade services and build niche groups around almost any topic, both in the US and internationally.

Operations: Reddit generates all of its US$2.5b revenue from its Internet Information Providers segment, with around US$2.0b from the United States and US$0.5b from the rest of the world.

Market Cap: US$30.0b

Investors who care about quality balance sheets and strong earnings trends may find Reddit worth a closer look. The company combines a sizeable US focused user base with high margin internet economics and strong recent revenue momentum from advertising and data licensing. At the same time, pricing assumes a premium P/E relative to many peers, and the dual class structure leaves outside shareholders with limited influence. Outcomes depend heavily on management execution on ad technology, AI data deals and the still early user economy. For investors trying to assess whether that trade off between growth potential and governance risk is acceptable, a key consideration is how durable Reddit’s monetization improvements and data advantages may be over the next few years.

Reddit’s accelerating ad and data story might look fully priced, but the real question is how far monetization can stretch before governance frictions start to bite. Review the analyst forecasts for Reddit to see what could change that balance.

Overview: Monster Beverage develops, markets, and distributes a wide range of energy drinks, flavored beverages, and related products across the globe, selling through grocery chains, convenience stores, e-commerce platforms, and other retail channels under well known brands such as Monster Energy, Reign, and Bang.

Operations: Monster Beverage generates most of its US$8.8b in revenue from Monster Energy Drinks at about US$8.1b, with additional contributions from Strategic Brands at roughly US$0.5b, Alcohol Brands at about US$0.1b, and Other at around US$24.3m. Sales span U.S. and Canada, EMEA, Latin America and Caribbean, and Asia Pacific.

Market Cap: US$84.4b

Monster Beverage earns attention from quality focused investors because it combines net margins of 23.1%, return on equity near 23.3%, and a deep global distribution tie up with Coca Cola, alongside growth levers in zero sugar offerings and international markets. Recent quarters show net sales above US$2.0b and record non U.S. revenue. Management highlights pressures from aluminum costs, foreign exchange swings, and lower margin emerging market growth that can affect profitability. The stock trades on a premium multiple and relies on higher risk external funding. A key consideration for investors is whether product development, brand strength, and cost discipline can support that premium as energy drink category dynamics and regulation evolve.

Monster Beverage’s premium P/E, strong margins and Coca Cola partnership suggest a story investors may be underestimating. Scan the analysis report for Monster Beverage to see what could challenge or reinforce that premium narrative.

Overview: Exelixis is an oncology focused biopharmaceutical company that develops and sells cancer medicines such as CABOMETYX and COMETRIQ, targeting hard to treat tumors where patients often have limited options.

Operations: Exelixis generates all of its US$2.4b in revenue from biotechnology, with around US$2.2b from the United States, US$161.0m from Europe and US$32.7m from Japan.

Market Cap: US$12.1b

Exelixis sits at an interesting crossroads for investors, with a high quality oncology franchise, strong balance sheet and very high 43.1% return on equity on one side, and heavy dependence on cabozantinib and rising pricing and reimbursement pressures on the other. CABOMETYX is still the engine of the story and recent quarter figures, including US$610.8m in Q1 2026 revenue and higher profit margins, show how powerful that engine can be when new patient starts are strong. At the same time, that concentration risk and growing 340B discounts keep future margins in question. In addition, an active buyback program, late stage assets like zanzalintinib and a P/E below many biotech peers create a setup where small shifts in trial outcomes, regulation or competitive data could matter a lot more than the headline multiple suggests.

Exelixis’ high 43.1% return on equity and oncology cash engine hint at a story investors may be underpricing. Weigh cabozantinib concentration, 340B pressure and late stage pipeline catalysts in the full narrative for Exelixis

The three stocks in this article are just a starting point. The full screener surfaced 41 more companies with high return on equity, robust past performance and solid balance sheets that deserve a place on your watchlist through the Solid Balance Sheet and Fundamentals screener. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction ideas from that broader group.

Take Control of Your Investment Journey

If Monster Beverage or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen.
Once you’ve made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.
Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.
By uncovering hidden catalysts and risks early, you’ll accelerate your decision-making and stay one step ahead of the market.

Curious To Explore Fresh Alternatives?

Some stocks are already building breakout momentum while most investors have not caught on yet. Before this edge drops into the crowd, scan fresh ideas and act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com